Immuno-Oncology Summitについて


Over the past 6 years, CHI's Immuno-Oncology Summit became the leading annual meeting focusing on the latest applied research. The comprehensive 5-day, 12-track program covers immunomodulatory antibody engineering and emerging immuno-oncology targets, combination immunotherapy, preclinical and translational IO, predictive biomarkers and companion diagnostics, adoptive T cell therapy, oncolytic viruses and personalized cancer vaccines.

The Immuno-Oncology Summit brings together a unique and international mix of large and medium pharmaceutical and biotech companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers-making the Summit a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. Now in its 6th year, the IO Summit consistently delivers a cutting-edge agenda, 600+ senior delegates, and a sold-out exhibit hall.

Please join us in Boston for comprehensive scientific coverage and unparalleled networking opportunities at CHI's Immuno-Oncology Summit 2018!

Why attend CHI's Immuno-Oncology Summit?
  • Network with 600+ IO thought leaders from 27 countries
  • Learn the latest developments in immuno-oncology from 150+ scientific presentations
  • Customize your comprehensive 5-day conference experience by selecting from 12-tracks, 2 training seminars, partnering forum and 4 dinner courses
  • Discover technology solutions from 40+ exhibitors
  • Brainstorm actionable solutions at the expertly-facilitated roundtable discussions
  • Develop new collaborations by networking with industry decision makers and leading academic researchers
  • Review the latest research from 40+ posters
  • Focus on your agenda by track hopping between concurrent tracks
  • Showcase your research by presenting a scientific poster
What's new in 2018?
  • New track on Bispecific Antibodies completes a 5-day offering on immunotherapy engineering
  • IO Biomarkers coverage expanded to 3 days to cover predictive biomarkers, companion diagnostics and immune profiling
  • Coverage of Adoptive T-Cell Therapy expanded to 3 days to span discovery and development
  • New track on Neoantigen Targeted Therapies highlights personalized immunotherapy approaches
  • New Partnering Forum highlights emerging companies and investment opportunities
  • Exhibit hall is expanded to accommodate increasing demand to showcase solution providers and posters
  • Training seminar and dinner course offering expanded
Choose your language
Traditional Chinese
Simplified Chinese